Mallinckrodt states positive results of Terlipressin in HRS-1 patients
Category: #health  By Nikita Chaurasia  Date: 2019-08-17
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Mallinckrodt states positive results of Terlipressin in HRS-1 patients
  • The company announced positive results from its Phase 3 CONFIRM trial of terlipressin in Hepatorenal Syndrome Type 1.
  • The study verified HRS-1 reversal along with other 3 components-renal function enhancement, escaping dialysis, and short-term survival.

UK based Mallinckrodt plc has reportedly announced positive results for its Phase 3 CONFIRM clinical study assessing the efficiency and safety of terlipressin in the HRS-1 patients. The study is said to have met the chief endpoint of authenticated HRS-1 reversal which includes 3 other components- renal function enhancement, escaping dialysis, and short-term survival.

For the uninitiated, CONFIRM is one of the largest prospective studies conducted in the patients suffering from HRS-1. Additionally, HRS-1 is a severe, erratic and acute disease categorized by complications of liver disease leading to kidney failure. It has a very poor prediction, with an average survival time of less than 2 weeks and greater than 80% mortality within three months.

It has been claimed that Mallinckrodt plans to file a new drug application to the U.S. Food and Drug Administration in the initial months of 2020.

Speaking on the matter, Steven Romano, Executive Vice President and Chief Scientific Officer at Mallinckrodt cited that the company is devoted to enhancing the therapies that treat underserved patients with critical and devastating conditions. He further added that Mallinckrodt is encouraged to have received the positive results of the CONFIRM trial in HRS-1. Additionally, the CONFIRM trial is expected to support the supervisory submissions of terlipressin as a treatment for the syndrome in the United States and Canada.

Meanwhile, Arun Sanyal, M.D., Z. Reno Vlahcevic, Professor of Medicine, Physiology and Molecular Pathology, Virginia Commonwealth University, stated that the preliminary results of the Phase 3 CONFIRM study demonstrated terlipressin reversing the course of HRS-1 by improving renal function, escaping dialysis and providing a short time survival.  

For the records, established in 1840, Mallinckrodt is involved in developing, manufacturing, marketing and delivering specialty pharmaceutical products & therapies globally.

Source credit: http://www.mallinckrodt.com/about/news-and-media/news-detail/?id=26066

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Spotify to allow access to all creators in its video podcast platform

Spotify to allow access to all creators in its video podcast platform

By Nikita Chaurasia

Audio streaming giant Spotify has announced the launch of its video podcast feature, which will be provided by its self-publishing podcast division, Anchor. According to sources, the feature will initially be offered on a rolling basis where interes...

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...